An investigation on behalf of investors of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) shares over potential securities laws violations by Osmotica Pharmaceuticals and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) concerning whether a series of statements by Osmotica Pharmaceuticals plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Bridgewater, NJ based Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. Osmotica Pharmaceuticals plc reported that its annual Total Revenue rose from $245.74 million in 2017 to $263.7 million in 2018 and that its Net Loss increased from $41.14 million in 2017 to $109.39 million in 2018.

On March 27, 2019, after the markets closed, Osmotica Pharmaceuticals plc announced preliminary results for a second Phase 3 clinical trial of arbaclofen extended-release tablets that failed to beat placebo as measured by the Clinical Global Impression of Change.